For: | Gyimesi M, Rauscher AÁ, Suthar SK, Hamow KÁ, Oravecz K, Lőrincz I, Borhegyi Z, Déri MT, Kiss ÁF, Monostory K, Szabó PT, Nag S, Tomasic I, Krans J, Tierney PJ, Kovács M, Kornya L, Málnási-Csizmadia A. Improved Inhibitory and Absorption, Distribution, Metabolism, Excretion, and Toxicology (ADMET) Properties of Blebbistatin Derivatives Indicate That Blebbistatin Scaffold Is Ideal for drug Development Targeting Myosin-2. J Pharmacol Exp Ther 2021;376:358-73. [PMID: 33468641 DOI: 10.1124/jpet.120.000167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis] |
---|
Number | Citing Articles |
1 | Forouzandehmehr M, Paci M, Koivumäki JT, Hyttinen J. Altered contractility in mutation-specific hypertrophic cardiomyopathy: A mechano-energetic in silico study with pharmacological insights. Front Physiol 2022;13. [DOI: 10.3389/fphys.2022.1010786] [Reference Citation Analysis] |
2 | Moussaoui D, Robblee JP, Auguin D, Fisher F, Fagnant PM, Macfarlane JE, Schaletzky J, Wehri E, Mueller-dieckmann C, Baum J, Robert-paganin J, Trybus KM, Houdusse A. Mechanism of small molecule inhibition of Plasmodium falciparum myosin A informs antimalarial drug design.. [DOI: 10.1101/2022.09.09.507123] [Reference Citation Analysis] |
3 | Lilienberg J, Hegyi Z, Szabó E, Hathy E, Málnási-Csizmadia A, Réthelyi JM, Apáti Á, Homolya L. Pharmacological Modulation of Neurite Outgrowth in Human Neural Progenitor Cells by Inhibiting Non-muscle Myosin II. Front Cell Dev Biol 2021;9:719636. [PMID: 34604221 DOI: 10.3389/fcell.2021.719636] [Cited by in F6Publishing: 1] [Reference Citation Analysis] |